Arecor Therapeutics Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Arecor Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of 251p. The average 1-year stock price forecast is 201.81% higher than the current stock price, while the lowest is 250p (+201.20%) and the highest is 251p (+202.41%).

Price Target: 251p (+201.81%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	250p	251p	251p	251p
Change	+201.20%	+201.81%	+201.81%	+202.41%

Analyst Ratings

The average analyst rating for Arecor Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Oct '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Financial Forecast

Revenue This Year

900.00K

from 1.71M

-47.49%

from 1.71M

Revenue Next Year

1.05M

from 900.00K

16.67%

from 900.00K

EPS This Year

-0.14

from 0.02

EPS Next Year

-0.13

from -0.14

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.16M	2.40M	4.57M	1.64M	1.71M	900.00K
Revenue Growth	-31.80%	107.51%	90.30%	-64.07%	4.32%	-47.49%
Operating Income	-5.98M	-10.34M	-9.18M	-5.18M	-4.05M	-5.90M
EPS	-	-	-	-	0.02	-0.14
Free Cash Flow	-	-	-	-	-2.46M	-4.36M
No. Analysts	-	-	-	-	-	1

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is GBP.

Revenue Forecast

Chart

Revenue	2026	2027
High	900,000
Avg	900,000
Low	900,000

Revenue Growth

Chart

Revenue Growth	2026	2027
High	-47.5%
Avg	-47.5%
Low	-47.5%

EPS Forecast

Chart

EPS	2026	2027
High	-0.14
Avg	-0.14
Low	-0.15

EPS Growth

Chart

EPS Growth	2026	2027
High	-
Avg	-
Low	-